Angiotensin-converting enzyme (ACE) inhibitors are well established as first-line therapy for
patients with left ventricular dysfunction, diabetic patients with hypertension or renal disease,
and patients recovering from myocardial infarction. Angiotensin II and bradykinin regulate
cellular proliferation, inflammation, and endothelial function, thus playing an important role
in the pathogenesis of atherosclerosis. A large body of experimental evidence reporting that
ACE inhibitors limit these effects has formed the rationale for major clinical trials of these …